A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

May 19, 2022

Primary Completion Date

May 26, 2025

Study Completion Date

May 26, 2025

Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
DRUG

STN1010904 ophthalmic suspension 0.03% BID

0.03% STN1010904 ophthalmic suspension BID

DRUG

STN1010904 ophthalmic suspension 0.1% BID

0.1% STN1010904 ophthalmic suspension BID

DRUG

Placebo (Vehicle) BID

Placebo (vehicle) BID

Trial Locations (15)

15213

UPMC, Pittsburgh

16066

Scott Christie and Associates, Cranberry Township

21287

Johns Hopkins University, Baltimore

42055

University Hospital of Saint-Etienne, Saint-Etienne

46260

Price Vision Group, Indianapolis

55905

Mayo Clinic, Rochester

63090

Comprehensive Eye Care, Ltd, Washington

64111

Tauber Eye Center, Kansas City

75019

Fondation Ophtalmologique Adolphe de Rothschild, Paris

90095

Stein Eye Institution UCLA, Los Angeles

97210

Devers Eye Institute, Portland

500034

Suven Clinical Research CenterL V Prasad Eye Institute, Banjara Hills

07650

Metropolitan Eye Research and Surgery Center, Palisades Park

77025-1697

Houston Eye Associates, Houston

600 006

Medical Research Foundation, Chennai

All Listed Sponsors
collaborator

ActualEyes Inc.

UNKNOWN

lead

Santen Inc.

INDUSTRY